Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,119 across all filing types
Latest filing 2021-01-06 Regulatory Filings
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Mayne Pharma launches Microgestin 24 FE tablets in the US 2 pages 168.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 7 January 2021 about the commercial launch of a pharmaceutical product, MICROGESTIN 24 FE tablets, in the United States. It includes product details, market context, company statements, contact information, and prescribing information. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a corporate announcement about a product launch rather than a financial report or regulatory filing. It is longer than 5,000 characters but does not contain financial data or management discussion. Therefore, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific categories.
2021-01-06 English
Mayne Pharma successfully extends debt facility 2 pages 150.4KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 18 December 2020 regarding Mayne Pharma's successful extension of its debt facility. It details the terms of the extended debt facilities, covenant terms, and financial metrics related to net financial debt and compliance. The content focuses on financing activities and capital structure updates rather than a full financial report or earnings release. The document length is 2764 characters, which is relatively short and typical for an announcement rather than a comprehensive report. There is no indication that this is a full annual or interim report, audit report, or earnings release. The primary subject is the extension of debt facilities and covenant terms, which fits the category of Capital/Financing Update (CAP).
2020-12-17 English
Appendix 3G 14 pages 396.4KB
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement from Mayne Pharma Group Limited regarding the issuance of employee long-term incentive plan securities, including loan shares, performance rights, and options. It includes an Appendix 3G, which is a standard ASX form used to notify the issue, conversion, or payment up of equity securities, particularly under employee incentive schemes. The content focuses on equity securities issuance to key management personnel and employees, with no financial statements or performance data. The document is regulatory in nature, reporting share issuance events rather than financial results or management commentary. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2020-12-03 English
Change of Director's Interest Notice 2 pages 187.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including number of shares held before and after the change, nature of the interest, and dates of changes. This type of document is a report of personal share transactions by company directors and executives, commonly known as insider trades. It is not a full financial report, earnings release, or management report. It fits precisely the definition of 'Director's Dealing' filings.
2020-12-03 English
Chairman and CEO's Addresses to Shareholders 21 pages 3.4MB
AGM Information Classification · 95% confidence The document is a detailed communication from Mayne Pharma Group Limited dated 24 November 2020, addressed to the ASX Limited regarding the Annual General Meeting (AGM) held on that date. It includes the Chairman's address and the CEO's address, both of which provide updates on company performance, strategic priorities, and operational details. The text explicitly states that these are presentations and addresses to shareholders delivered at the AGM. The content is consistent with materials typically shared during an AGM, including procedural details, business updates, and strategic outlooks. There is no indication that this is a full annual report, earnings release, or other financial filing. The document is not merely an announcement of a report but contains substantive presentation content. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (15,000 characters) supports that this is a full presentation rather than a brief announcement.
2020-11-23 English
2020 AGM Results 2 pages 203.5KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal communication to the ASX regarding the results of the Annual General Meeting (AGM) of Mayne Pharma Group Limited held on 24 November 2020. It includes detailed voting results for resolutions such as re-election of directors and adoption of the remuneration report. The document references compliance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act, which pertain to disclosure of voting results. The content is focused on announcing the official voting outcomes rather than providing the AGM materials or presentations themselves. The document length is relatively short (2659 characters), consistent with a voting results announcement rather than a full AGM report or presentation. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA).
2020-11-23 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.